Astria Therapeutics (NASDAQ:ATXS) Rating Increased to Strong-Buy at Cantor Fitzgerald

Astria Therapeutics (NASDAQ:ATXS) was upgraded by equities research analysts at Cantor Fitzgerald to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

Several other research analysts have also issued reports on the stock. JMP Securities initiated coverage on shares of Astria Therapeutics in a research note on Friday, January 31st. They issued an “outperform” rating and a $26.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and issued a $28.00 price objective (up from $27.00) on shares of Astria Therapeutics in a research note on Wednesday, March 12th. Citizens Jmp upgraded shares of Astria Therapeutics to a “strong-buy” rating in a research report on Friday, January 31st. Finally, HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a research note on Tuesday, March 11th. Five research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Astria Therapeutics presently has a consensus rating of “Buy” and an average target price of $30.00.

Astria Therapeutics Stock Performance

NASDAQ:ATXS opened at $5.16 on Tuesday. The company has a market cap of $291.20 million, a price-to-earnings ratio of -2.47 and a beta of 0.68. The stock’s fifty day moving average price is $5.45 and its two-hundred day moving average price is $7.99. Astria Therapeutics has a 52-week low of $3.56 and a 52-week high of $12.92.

Astria Therapeutics (NASDAQ:ATXS) last issued its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.01. On average, equities analysts predict that Astria Therapeutics will post -1.65 EPS for the current fiscal year.

Hedge Funds Weigh In On Astria Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ATXS. Rhumbline Advisers increased its holdings in shares of Astria Therapeutics by 2.3% in the fourth quarter. Rhumbline Advisers now owns 62,163 shares of the biotechnology company’s stock worth $556,000 after acquiring an additional 1,381 shares in the last quarter. Hsbc Holdings PLC lifted its holdings in shares of Astria Therapeutics by 9.0% during the 4th quarter. Hsbc Holdings PLC now owns 19,263 shares of the biotechnology company’s stock valued at $170,000 after purchasing an additional 1,587 shares in the last quarter. Legal & General Group Plc grew its position in shares of Astria Therapeutics by 7.6% in the 4th quarter. Legal & General Group Plc now owns 31,418 shares of the biotechnology company’s stock valued at $281,000 after purchasing an additional 2,222 shares during the period. Tower Research Capital LLC TRC increased its stake in Astria Therapeutics by 109.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 2,766 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Astria Therapeutics by 19.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 17,762 shares of the biotechnology company’s stock worth $159,000 after buying an additional 2,878 shares during the period. Institutional investors and hedge funds own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.